REGNRegeneron PharmaceuticalsSigning up patients
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age-related Macular Degeneration (AMD) · Geographic Atrophy (GA)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 975 (planned)
- Started
- Oct 30, 2024
- Main results expected
- Jul 31, 2028
- Fully finished
- Apr 9, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline, measured by Fundus Autofluorescence (FAF)
Measured over: To week 52
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06541704 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC